|Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practiceá…|
AC Wolff, MEH Hammond, DG Hicks, M Dowsett, LM McShane, ...
Archives of Pathology and Laboratory Medicine 138 (2), 241-256, 2013
|Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group|
M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ...
Journal of the National Cancer Institute, 2011
|A short history of the polymerase chain reaction|
JMS Bartlett, D Stirling
PCR protocols, 3-6, 2003
|Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer|
CJ Witton, JR Reeves, JJ Going, TG Cooke, J Bartlett
The Journal of pathology 200 (3), 290-297, 2003
|Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations|
G Sauter, J Lee, JMS Bartlett, DJ Slamon, MF Press
Journal of Clinical Oncology 27 (8), 1323-1333, 2009
|Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer|
J Edwards, NS Krishna, KM Grigor, JMS Bartlett
British journal of cancer 89 (3), 552-556, 2003
|An international Ki67 reproducibility study|
MYC Polley, SCY Leung, LM McShane, D Gao, JC Hugh, ...
Journal of the National Cancer Institute, djt306, 2013
|Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial|
CJH Van de Velde, D Rea, C Seynaeve, H Putter, A Hasenburg, ...
The Lancet 377 (9762), 321-331, 2011
|Multidisciplinary meeting on male breast cancer: summary and research recommendations|
LA Korde, JA Zujewski, L Kamin, S Giordano, S Domchek, WF Anderson, ...
Journal of Clinical Oncology 28 (12), 2114-2122, 2010
|Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients|
HR Ali, E Provenzano, SJ Dawson, FM Blows, B Liu, M Shah, HM Earl, ...
Annals of Oncology 25 (8), 1536-1543, 2014
|AKT activation predicts outcome in breast cancer patients treated with tamoxifen|
T Kirkegaard, CJ Witton, LM McGlynn, SM Tovey, B Dunne, A Lyon, ...
The Journal of pathology 207 (2), 139-146, 2005
|Evaluating HER2 amplification and overexpression in breast cancer|
J Bartlett, JJ Going, EA Mallon, AD Watters, JR Reeves, P Stanton, ...
The Journal of pathology 195 (4), 422-428, 2001
|Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres|
M Dowsett, J Bartlett, IO Ellis, J Salter, M Hills, E Mallon, AD Watters, ...
The Journal of pathology 199 (4), 418-423, 2003
|The androgen receptor and signal‐transduction pathways in hormone‐refractory prostate cancer. Part 1: modifications to the androgen receptor|
J Edwards, J Bartlett
BJU international 95 (9), 1320-1326, 2005
|The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.|
JM Bartlett, SP Langdon, BJ Simpson, M Stewart, D Katsaros, P Sismondi, ...
British Journal of Cancer 73 (3), 301, 1996
|A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns|
F Notta, M Chan-Seng-Yue, M Lemire, Y Li, GW Wilson, AA Connor, ...
|Observer variation in immunohistochemical analysis of protein expression, time for a change?|
T Kirkegaard, J Edwards, S Tovey, LM McGlynn, SN Krishna, ...
Histopathology 48 (7), 787-794, 2006
|Best Practice No 176 Updated recommendations for HER2 testing in the UK|
IO Ellis, J Bartlett, M Dowsett, S Humphreys, B Jasani, K Miller, SE Pinder, ...
Journal of clinical pathology 57 (3), 233-237, 2004
|The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells|
A Naresh, W Long, GA Vidal, WC Wimley, L Marrero, CI Sartor, S Tovey, ...
Cancer Research 66 (12), 6412-6420, 2006
|Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer|
AM Al Murri, JMS Bartlett, PA Canney, JC Doughty, C Wilson, ...
British journal of cancer 94 (2), 227-230, 2006